↓ Skip to main content

A phase I/II trial of beta-(1,3)/(1,6) D-glucan in the treatment of patients with advanced malignancies receiving chemotherapy

Overview of attention for article published in Journal of Experimental & Clinical Cancer Research, September 2008
Altmetric Badge

About this Attention Score

  • Above-average Attention Score compared to outputs of the same age (52nd percentile)
  • Good Attention Score compared to outputs of the same age and source (75th percentile)

Mentioned by

twitter
1 tweeter
facebook
2 Facebook pages

Citations

dimensions_citation
32 Dimensions

Readers on

mendeley
57 Mendeley
citeulike
1 CiteULike
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
A phase I/II trial of beta-(1,3)/(1,6) D-glucan in the treatment of patients with advanced malignancies receiving chemotherapy
Published in
Journal of Experimental & Clinical Cancer Research, September 2008
DOI 10.1186/1756-9966-27-40
Pubmed ID
Authors

Alan B Weitberg

Abstract

Beta-(1,3)/(1,6) D-glucan, a component of the fungal cell wall, has been shown to stimulate the immune system, enhance hematopoiesis, amplify killing of opsonized tumor cells and increase neutrophil chemotaxis and adhesion. In view of these attributes, the beta-glucans should be studied for both their therapeutic efficacy in patients with cancer as well as an adjunctive therapy in patients receiving chemotherapy as a maneuver to limit suppression of hematopoiesis.In this study, twenty patients with advanced malignancies receiving chemotherapy were given a beta-(1,3)/(1,6) D-glucan preparation (MacroForce plus IP6, ImmuDyne, Inc.) and monitored for tolerability and effect on hematopoiesis. Our results lead us to conclude that beta-glucan is well-tolerated in cancer patients receiving chemotherapy, may have a beneficial effect on hematopoiesis in these patients and should be studied further, especially in patients with chronic lymphocytic leukemia and lymphoma.

Twitter Demographics

The data shown below were collected from the profile of 1 tweeter who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 57 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
United Kingdom 1 2%
United States 1 2%
Australia 1 2%
Unknown 54 95%

Demographic breakdown

Readers by professional status Count As %
Researcher 21 37%
Student > Master 8 14%
Other 6 11%
Professor > Associate Professor 5 9%
Student > Ph. D. Student 4 7%
Other 10 18%
Unknown 3 5%
Readers by discipline Count As %
Medicine and Dentistry 23 40%
Agricultural and Biological Sciences 18 32%
Chemistry 3 5%
Biochemistry, Genetics and Molecular Biology 2 4%
Chemical Engineering 1 2%
Other 3 5%
Unknown 7 12%

Attention Score in Context

This research output has an Altmetric Attention Score of 2. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 25 April 2016.
All research outputs
#3,479,149
of 7,601,780 outputs
Outputs from Journal of Experimental & Clinical Cancer Research
#97
of 402 outputs
Outputs of similar age
#88,966
of 200,183 outputs
Outputs of similar age from Journal of Experimental & Clinical Cancer Research
#2
of 12 outputs
Altmetric has tracked 7,601,780 research outputs across all sources so far. This one has received more attention than most of these and is in the 51st percentile.
So far Altmetric has tracked 402 research outputs from this source. They receive a mean Attention Score of 1.5. This one has gotten more attention than average, scoring higher than 73% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 200,183 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 52% of its contemporaries.
We're also able to compare this research output to 12 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 75% of its contemporaries.